Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from Corum Group Limited ( (AU:PHX) ).
Pharmx Technologies Limited announced strong interim results for the half-year ended December 2024, with revenues reaching $3.8 million, a 17% increase from the previous period. The company has secured a commercial agreement with Toniq, expanding its reach to 99% of New Zealand pharmacies, and terminated a revenue share agreement with Alchemy, reducing costs by $0.8 million. Despite a slight decline in EBITDA and cash position, Pharmx maintained a robust financial standing, supporting its growth agenda through increased investment in technology and market expansion.
More about Corum Group Limited
Pharmx Technologies Limited is a company operating in the pharmaceutical technology industry, providing a suite of products and services aimed at enhancing account connections and transaction values. The company focuses on expanding its market presence, particularly in New Zealand, and improving its technological capabilities to support growth.
YTD Price Performance: 12.16%
Average Trading Volume: 797,491
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$49.68M
For a thorough assessment of PHX stock, go to TipRanks’ Stock Analysis page.
